The deal marks a noteworthy development for Ro, which has been one of the major telehealth platforms providing compounded copies of GLP-1 obesity drugs during shortages of the branded treatments. Lilly has harshly criticized the cheaper products made by compounding pharmacies — going so far as to send cease-and-desist letters to telehealth sites offering compounded products.
